Financial reports
ARS
2023 FY
Annual report to shareholders
22 Apr 24
10-K
2023 FY
Annual report
4 Mar 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
7 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
20 Apr 23
10-K
2022 FY
Annual report
22 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
Current reports
8-K
Departure of Directors or Certain Officers
9 Apr 24
8-K
Other Events
25 Mar 24
8-K
Entry into a Material Definitive Agreement
4 Mar 24
8-K
Astria Therapeutics Announces Pricing of $125 Million Underwritten Offering
31 Jan 24
8-K
Other Events
30 Jan 24
8-K
Entry into a Material Definitive Agreement
5 Jan 24
8-K
Departure of Directors or Certain Officers
20 Dec 23
8-K
Astria Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update
13 Nov 23
8-K
Astria Therapeutics Announces Pricing of $64 Million Underwritten Offering
12 Oct 23
8-K
Other Events
12 Oct 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
4 Mar 24
424B5
Prospectus supplement for primary offering
31 Jan 24
S-3/A
Shelf registration (amended)
28 Dec 23
S-3
Shelf registration
15 Dec 23
424B5
Prospectus supplement for primary offering
12 Oct 23
FWP
Free writing prospectus
11 Oct 23
S-8
Registration of securities for employees
7 Aug 23
S-3
Shelf registration
11 May 23
424B5
Prospectus supplement for primary offering
15 Dec 22
424B5
Prospectus supplement for primary offering
10 Nov 22
Proxies
DEFA14A
Additional proxy soliciting materials
22 Apr 24
DEF 14A
Definitive proxy
22 Apr 24
DEFA14A
Additional proxy soliciting materials
20 Apr 23
DEF 14A
Definitive proxy
20 Apr 23
PRE 14A
Preliminary proxy
6 Apr 23
DEFA14A
Additional proxy soliciting materials
27 Apr 22
DEF 14A
Definitive proxy
27 Apr 22
DEFA14A
Additional proxy soliciting materials
4 Nov 21
DEF 14A
Definitive proxy
4 Nov 21
PRE 14A
Preliminary proxy
25 Oct 21
Other
EFFECT
Notice of effectiveness
2 Jan 24
CORRESP
Correspondence with SEC
28 Dec 23
CORRESP
Correspondence with SEC
28 Dec 23
UPLOAD
Letter from SEC
27 Dec 23
EFFECT
Notice of effectiveness
24 May 23
CORRESP
Correspondence with SEC
18 May 23
UPLOAD
Letter from SEC
17 May 23
EFFECT
Notice of effectiveness
24 May 22
CORRESP
Correspondence with SEC
19 May 22
UPLOAD
Letter from SEC
18 May 22
Ownership
4
SUNIL AGARWAL
9 Apr 24
3
SUNIL AGARWAL
9 Apr 24
4
Christopher Morabito
3 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
SC 13G/A
FMR LLC
11 Mar 24
SC 13G/A
BlackRock Inc.
7 Mar 24
SC 13G/A
Fairmount Funds Management LLC
14 Feb 24
SC 13G/A
Cormorant Asset Management, LP
14 Feb 24
SC 13G/A
Deep Track Capital, LP
14 Feb 24
SC 13G/A
Vivo Opportunity, LLC
13 Feb 24